Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.

ABSTRACT:

Background

Systemic therapy combined with transcatheter arterial chemoembolization (TACE) is the main treatment strategy for patients with unresectable hepatocellular carcinoma (uHCC). Nevertheless, there are currently few direct comparative studies between different combined treatment regimens. Therefore, this study aims to compare the efficacy and safety of sintilimab and bevacizumab biosimilar (IBI305) versus PD-1 inhibitor and tyrosine kinase inhibitor (TKI) combined with TACE in the treatment of uHCC.

Methods

This retrospective study included 225 patients with uHCC who received either TACE combined with sintilimab and IBI305 (TSB group, n = 84) or other PD-1 inhibitors and TKIs (TTP group, n = 141). This study evaluated overall survival (OS) as the primary outcome, with

SUBMITTER: Ya H 

PROVIDER: S-EPMC12908432 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature